CXCL8 binding nucleic acids

Abstract

The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′[SEQ. ID. NO: 27], wherein Xu is U or absent.

The invention claimed is: 
     
       1. An L-nucleic acid molecule that binds human CXCL8 comprising one of SEQ ID NOs:14-26, and 39-44. 
     
     
       2. The L-nucleic acid molecule of  claim 1 , wherein said L-nucleic acid molecule consists of ribonucleotides. 
     
     
       3. The L-nucleic acid molecule of  claim 1 , wherein said L-nucleic acid molecule comprises a modification group, wherein said modification group comprises a polyethylene glycol. 
     
     
       4. The L- nucleic acid molecule of  claim 3 , wherein the modification group is selected from the group consisting of a linear polyethylene glycol and a branched polyethylene glycol. 
     
     
       5. The L-nucleic acid molecule of  claim 3 , wherein said polyethylene glycol comprises a molecular weight of about 40,000 Da. 
     
     
       6. The L-nucleic acid molecule of  claim 1 , wherein said L-nucleic acid molecule comprises a modification group, wherein said modification group immobilizes said L-nucleic acid molecule. 
     
     
       7. The L-nucleic acid molecule of  claim 1 , wherein said L-nucleic acid molecule comprises a modification group, wherein said modification group is detectable. 
     
     
       8. The L- nucleic acid molecule of  claim 1  comprising the nucleotide sequence of SEQ ID NO:17. 
     
     
       9. The L-nucleic acid molecule of  claim 8 , wherein said L-nucleic acid molecule comprises a modification group comprising a polyethylene glycol. 
     
     
       10. The L-nucleic acid molecule of  claim 9 , wherein said polyethylene glycol comprises a molecular weight of about 40,000 Da. 
     
     
       11. The L-nucleic acid molecule of  claim 9 , wherein said modification group comprises a linear polyethylene glycol or a branched polyethylene glycol. 
     
     
       12. The L- nucleic acid molecule of  claim 1 , comprising the nucleotide sequence of SEQ ID NO:20. 
     
     
       13. The L-nucleic acid molecule of  claim 12 , wherein said L-nucleic acid molecule comprises a modification group comprising a polyethylene glycol. 
     
     
       14. The L-nucleic acid molecule of  claim 13 , wherein said polyethylene glycol comprises a molecular weight of about 40,000 Da. 
     
     
       15. The L-nucleic acid molecule of  claim 13 , wherein said modification group comprises a linear polyethylene glycol or a branched polyethylene glycol. 
     
     
       16. A pharmaceutical composition comprising said L-nucleic acid molecule as defined in  claim 1  and optionally a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier or a pharmaceutically active agent. 
     
     
       17. A complex comprising said L-nucleic acid molecule of  claim 1  and CXCL8. 
     
     
       18. A kit for the detection of CXCL8, comprising the L-nucleic acid molecule of  claim 1 , and at least an instruction leaflet or a reaction vessel. 
     
     
       19. A method for the detection of the L-nucleic acid as defined in  claim 1  in a sample, wherein the method comprises the steps of:
 a) providing a capture probe, wherein the capture probe is at least partially complementary to a first part of the L-nucleic acid molecule as defined in  claim 1  and a detection probe, wherein the detection probe is at least partially complementary to a second part of the L-nucleic acid molecule as defined in  claim 1 , or, alternatively, the capture probe is at least partially complementary to a second part of the L-nucleic acid molecule as defined in  claim 1  and the detection probe is at least partially complementary to a first part of the L-nucleic acid molecule as defined in  claim 1 ; 
 b) adding the capture probe and the detection probe separately or combined to a sample containing the L-nucleic acid molecule as defined in  claim 1  or presumed to contain the L-nucleic acid molecule as defined in  claim 1 ; 
 c) allowing the capture probe and the detection probe to react either simultaneously or in any order sequentially with the L-nucleic acid molecule as defined in  claim 1  or part thereof, 
 d) optionally detecting whether or not the capture probe is hybridized to the L-nucleic acid molecule as defined in  claim 1  provided in step a); and 
 e) detecting the complex formed in step c) consisting of the L-nucleic acid molecule as defined in  claim 1  and the capture probe and the detection probe. 
 
     
     
       20. A method for the detection of CXCL8 comprising the steps of:
 a) providing a sample with unknown concentration of CXCL8; 
 b) bringing the sample or a dilution thereof in contact with the L-nucleic acid as defined in  claim 7 ; and 
 c) measuring the detectable modification group; 
 d) optionally, comparing signal from said detectable modification group with signal of a reference; or 
 e) optionally, comparing signal from said detectable modification group with signal of a sample of known CXCL8 concentration. 
 
     
     
       21. The method of  claim 1 , comprising step e).